ORIGINAL RESEARCH PAPER
Volume - 14 | Issue - 11 | November - 2025 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

EMERGING VACCINES AND MONOCLONAL ANTIBODY THERAPIES IN PEDIATRIC INFECTIOUS DISEASES

General Medicine

Dr Ravi Gupta Pediatrician, MBBS FRPCH UK, Mediclinic Welcare Hospital, Garhoud Dubai

Dr. Shahid Afzal* Pediatrician, MBBS FRPCH UK, Mediclinic Welcare Hospital, Garhoud Dubai
*Corresponding Author

ABSTRACT

Background: Pediatric infectious diseases continue to impose major morbidity and mortality worldwide, particularly from respiratory syncytial virus (RSV), coronavirus disease 2019 (COVID-19), dengue, and influenza. Recent advances in vaccinology and monoclonal antibody (mAb) platforms have transformed prophylaxis in infancy and early childhood. This review synthesizes current evidence on vaccine and mAb innovations, emphasizing clinical efficacy, safety, implementation feasibility, and cost-effectiveness from a physician's perspective. **Methods:** A narrative synthesis of peer-reviewed clinical trials, guideline statements, and cost-modeling analyses published between 2020 and 2025 was undertaken, focusing on pediatric populations and preventive immunotherapeutics. **Results:** Novel maternal and infant RSV vaccines (RSVpreF, nirsevimab), updated pediatric COVID-19 mRNA formulations, live-attenuated and tetravalent dengue vaccines (TAK-003), and next-generation universal influenza candidates have demonstrated robust immunogenicity and safety in children. Long-acting mAbs now offer season-long passive protection. Despite scientific progress, equitable rollout remains constrained by pricing, regulatory delays, and cold-chain demands. **Conclusion:** Integrating vaccine and mAb strategies through maternal immunization, infant protection, and strengthened public-health delivery can drastically reduce preventable pediatric mortality. Clinician involvement in surveillance, advocacy, and translational research is pivotal for sustaining these gains.

KEYWORDS

Pediatric Vaccination; Monoclonal Antibodies; RSV; COVID-19; Dengue; Influenza.

INTRODUCTION

Childhood infections remain among the foremost causes of global mortality despite decades of immunization initiatives. The World Health Organization estimates that over 1.2 million deaths annually occur among children < 5 years due to vaccine-preventable diseases, a burden magnified in low- and middle-income countries (LMICs).[1]

In the post-COVID-19 era, clinicians have witnessed both the vulnerability and resilience of pediatric populations. Emerging pathogens and viral variants demand dynamic immunization paradigms that extend beyond traditional live or inactivated vaccines. Two complementary technical advances have changed the landscape. First, modern vaccine platforms—stabilized viral surface proteins, protein nanoparticles, adjuvanted subunit vaccines, and mRNA—have improved immunogenicity and allowed more rapid iteration of strain composition. Second, long-acting monoclonal antibodies that provide passive immunity for months after a single dose now enable protection during the window of greatest risk when active vaccination is either infeasible or suboptimal. Table 1 shows estimates representing approximate annual global pediatric cases and deaths (2023-2025).[2][3]

Table 1. Global Burden of Pediatric Infectious Diseases (RSV, COVID-19, Dengue, Influenza)

Disease	Annual Pediatric Cases (approx.)	Estimated Deaths (<5 yrs)	Primary Mode of Transmission	Key Preventive Tools
RSV	33 million	≈ 100,000	Respiratory droplets	Maternal RSVpreF vaccine, Nirsevimab
COVID-19	> 25 million	> 40,000	Aerosol/ contact	Pediatric mRNA vaccines, booster strategies
Dengue	~ 9 million	> 10,000	Aedes mosquito	TAK-003 tetravalent vaccine
Influenza	> 15 million	> 20,000	Respiratory droplets	Annual quadrivalent vaccines, mAb adjuncts

Immunological and Therapeutic Rationale

The physician's understanding of immunological rationale bridges the microscopic principles of adaptive immunity with bedside preventive practice. Active immunization engages the host's immune machinery through controlled antigenic stimulation, enabling clonal expansion of B and T lymphocytes and the formation of long-lived plasma and memory cells. This process is the foundation of herd protection—by interrupting chains of transmission, vaccinated cohorts indirectly safeguard vulnerable infants and immunocompromised children. For clinicians, recognizing the temporal dynamics of this response is crucial: seroconversion typically follows a 10–14-day latency, and booster schedules are designed to consolidate immunological memory through affinity maturation within germinal centers.[4]

In contrast, passive immunization via monoclonal antibodies (mAbs) represents the therapeutic application of ready-made immune effector molecules. Engineered IgG1 or IgG4 subclasses are designed for high-affinity binding to critical viral epitopes, rapidly neutralizing circulating virions. From a pediatric clinician's perspective, mAbs fill a vital niche—newborns, preterm infants, and children with primary or secondary immunodeficiencies cannot generate reliable vaccine-mediated responses. Administering neutralizing antibodies confers immediate protection during epidemics or seasonal peaks.Molecular advances, particularly Fc-region engineering that prolongs half-life through neonatal Fc-receptor recycling, have transformed mAbs from short-acting adjuncts into season-long prophylactics. For example, nirsevimab maintains protective serum concentrations for up to five months, eliminating the need for multiple injections. Clinicians must appreciate pharmacokinetic variations influenced by age, weight, and comorbidities, as these determine dosing intervals and efficacy.The therapeutic rationale also encompasses immunopathological considerations. Pediatricians must weigh the risk of immune enhancement phenomena such as antibody-dependent enhancement (ADE) observed in dengue or immune-complex-mediated inflammation in RSV, against the benefits of antibody therapy. Rational immunoprophylaxis therefore demands an understanding of both protective and potentially pathogenic immune responses.[5]

From a translational standpoint, immunological knowledge guides vaccine–mAb integration strategies. Maternal immunization leverages the natural transplacental transfer of IgG during the third trimester, complementing infant passive immunization in the first months of life. This dual approach extends the protective window without compromising the infant's later vaccine responsiveness. Finally, in a health-systems context, physicians serve as the interface between molecular innovation and population impact. Interpreting immunogenicity data, correlates of protection (antibody titers, neutralizing activity), and breakthrough infection profiles enables evidence-based recommendations. The modern clinician thus acts simultaneously as immunologist, epidemiologist, and public-health advocate, ensuring that immunological rationale translates into therapeutic reality for every child.[6]

Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV) remains a leading cause of lower

respiratory tract infections in infants and young children worldwide, contributing significantly to pediatric hospitalizations during seasonal outbreaks. From a clinician's perspective, the burden of RSV extends beyond its immediate morbidity, it serves as a precursor to chronic respiratory complications such as recurrent wheezing and asthma in later childhood. Pediatricians and neonatologists encounter RSV bronchiolitis frequently, especially in premature infants, those with bronchopulmonary dysplasia, or congenital heart disease, underscoring the need for sustained preventive strategies.

Clinical Understanding and Pathophysiology

RSV primarily infects ciliated epithelial cells of the respiratory tract, leading to necrosis, mucus hypersecretion, and airway obstruction. The hallmark clinical picture includes cough, tachypnea, wheezing, and in severe cases, apnea or hypoxemia. From a doctor's standpoint, the emphasis is on early identification of high-risk infants, appropriate oxygen therapy, hydration, and infection control measures. Despite the high disease burden, antiviral treatments such as ribavirin have limited efficacy, making immunoprophylaxis the cornerstone of RSV management.

Advances in Vaccines and Monoclonal Antibodies

The recent approval of maternal RSVpreF vaccines (Pfizer and GSK) represents a major advance. By stimulating maternal IgG that crosses the placenta, infants gain passive protection for the first 6 months of life, the period of highest risk. Clinically, obstetricians and pediatricians must collaborate to integrate maternal vaccination into antenatal care, ensuring broad coverage before RSV season onset.[7] Monoclonal antibody prophylaxis has also evolved significantly. Palivizumab, though effective, required monthly injections, limiting its practicality. The newer nirsevimab, engineered for extended half-life, provides up to five months of protection with a single dose. This simplifies implementation and improves adherence. Clinicians should anticipate its integration into national immunization programs, prioritizing premature and medically complex infants.

Clinical Integration and Challenges

The physician's challenge lies not only in prescribing but also in advocating equitable access. The high cost of monoclonal antibodies has restricted their use primarily to tertiary-care settings. Pediatric practitioners play an essential role in identifying eligible infants, guiding parents, and reporting safety outcomes to strengthen post-marketing surveillance. In conclusion, RSV prevention exemplifies the modern integration of immunology into clinical pediatrics. For doctors, it demands balancing individual patient needs with population-level prevention, leveraging maternal vaccination and monoclonal antibody prophylaxis to reduce the global burden of RSV-associated morbidity and mortality in early life.[8]

Covid-19

In pediatric practice, COVID-19 has demonstrated a unique epidemiologic and immunologic profile. Most children experience mild or asymptomatic infection; however, clinicians recognize a small subset who progress to multisystem inflammatory syndrome in children (MIS-C)-a severe, post-infectious hyper-inflammatory state affecting the heart, gastrointestinal tract, and vasculature. Pediatricians must distinguish MIS-C from Kawasaki disease and bacterial sepsis, as prompt immunomodulatory therapy (IVIG, corticosteroids) is lifesaving. From an immunologic standpoint, children's relatively preserved innate responses and lower ACE2 receptor density confer partial protection, yet viral variants have narrowed this advantage. The clinical burden shifted toward unvaccinated school-age children and those with chronic illnesses. Hence, vaccination remains the primary preventive strategy. mRNA-based pediatric vaccines—Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273)—have shown >90 % seroconversion with favorable safety profiles in children 5–17 years old. Reduced-dose formulations mitigate myocarditis risk while maintaining neutralizing titers. For clinicians, vaccine selection depends on age, comorbidity, and national availability. Booster schedules are tailored to immune durability, especially in children receiving immunosuppressive therapy. Beyond vaccines, monoclonal antibody therapies such as tixagevimab/cilgavimab (Evusheld) and sotrovimab were introduced for high-risk or immunocompromised pediatric patients. These antibodies bind distinct epitopes of the SARS-CoV-2 spike protein, neutralizing viral entry. However, the rapid emergence of Omicron subvariants reduced their efficacy, emphasizing the need for continuous surveillance and antibody redesign. Physicians must remain informed about variant-specific guidance, as susceptibility profiles evolve every few months.[9] In hospital settings, management has expanded from supportive care to targeted immunotherapy and antiviral use (remdesivir, nirmatrelvir/ritonavir) in select pediatric cases. Clinicians play a pivotal role in identifying candidates for these interventions and counseling families on benefit-risk balance. Public-health implications are equally significant. Pediatric vaccination indirectly protects adults by reducing household transmission chains, a point physicians must reinforce to hesitant caregivers.Continuous clinician engagement in vaccine advocacy, registry participation, and variant tracking ensures that scientific innovation translates into sustained child health protection.[10]

Dengue

Dengue remains a formidable clinical challenge in pediatric practice, particularly across tropical and subtropical regions. Caused by four antigenically distinct DENV serotypes (DENV-1 to DENV-4) transmitted by Aedes mosquitoes, the disease manifests in children with a wide clinical spectrum, from mild febrile illness to life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). For clinicians, differentiating dengue from other febrile illnesses during early presentation is critical, as disease progression can be rapid within the critical defervescence period (days 3–7).[11] Pathophysiologically, dengue in children is marked by capillary permeability, thrombocytopenia, and cytokine storm. A pivotal immunological concern for physicians is antibody-dependent enhancement (ADE), where non-neutralizing or sub-neutralizing antibodies from a prior infection facilitate viral entry into Fc receptor–bearing cells, intensifying viral replication and inflammation. This mechanism has profound implications for vaccine and monoclonal antibody development, demanding a nuanced clinical and immunological understanding. The earlier vaccine CYD-TDV (Dengvaxia) demonstrated partial efficacy but increased hospitalization risk in seronegative children, making serological screening essential before administration, a practical challenge in resource-limited settings. The newer TAK-003 (QDENGA), a live-attenuated tetravalent vaccine, has shown approximately 80% efficacy in preventing hospitalization across serotypes without notable safety concerns. Clinicians must stay updated on evolving WHO recommendations, as vaccine deployment strategies differ depending on local serotype prevalence and age-based seropositivity patterns. From a therapeutic standpoint, there is currently no licensed antiviral or monoclonal antibody treatment for dengue, though E-protein–targeting mAbs are under clinical evaluation. Physicians managing dengue must rely on meticulous supportive care, fluid management, careful monitoring of hematocrit and platelet counts, and early recognition of shock. In the context of public health, pediatricians and community physicians are key players in surveillance and vaccine rollout. Educating families about mosquito control, symptom vigilance, and timely hospital referral forms the cornerstone of dengue management. Ultimately, dengue underscores the intersection of immunology, epidemiology, and bedside medicine. For the practicing doctor, integrating evolving vaccine science with careful clinical observation remains the best defense against this unpredictable pediatric pathogen.[12]

Influenza

Influenza continues to pose a significant clinical burden among pediatric populations, accounting for millions of hospitalizations and tens of thousands of deaths annually. Children under five years—especially those below two—represent the most vulnerable group due to immature immune responses and smaller airway anatomy. Clinically, influenza presents with abrupt-onset fever, myalgia, cough, and malaise; however, in infants, nonspecific features such as poor feeding, lethargy, or apnea may dominate. Pediatricians recognize influenza not merely as a self-limiting respiratory infection but as a potential trigger for severe secondary bacterial pneumonia, myocarditis, and encephalopathy. From an immunological standpoint, influenza's greatest challenge is its antigenic variability. Frequent antigenic drift (point mutations in the hemagglutinin [HA] and neuraminidase [NA] genes) enables seasonal reinfections, while occasional antigenic shift produces pandemics when novel subtypes emerge. This rapid evolution forces annual reformulation of vaccines and complicates herd immunity. The standard of care involves annual vaccination, recommended for all children above six months of age. Quadrivalent inactivated influenza vaccines (QIVs) currently cover the predominant A/H1N1, A/H3N2, and B/Yamagata/B/Victoria lineages. Recent advances include cell-based and recombinant HA vaccines, offering higher purity and reduced egg-adapted mutations, and mRNA influenza vaccines, now entering phase III trials. These

next-generation platforms aim to induce stronger and broader cross-protection against antigenically diverse strains. Clinicians should remain informed about these emerging formulations, which may soon replace conventional egg-based products.[13] In parallel, monoclonal antibody therapies such as VIS410 and MHAA4549A target conserved HA stem epitopes, neutralizing multiple influenza subtypes. Though currently investigational, these agents could serve as prophylaxis for immunocompromised or high-risk pediatric patients during outbreaks, particularly when vaccine mismatch occurs. From a physician's perspective, the clinical approach to pediatric influenza extends beyond immunization. Early antiviral therapy (oseltamivir) within 48 hours of symptom onset reduces complications and hospital stay. Physicians must also monitor for bacterial co-infection and manage dehydration aggressively. On a broader scale, influenza highlights the need for integrated seasonal surveillance and physician-led vaccine advocacy. Pediatricians serve as the front line in both clinical care and community education, ensuring timely vaccination and early detection of epidemic trends. In this sense, the influenza experience embodies the physician's dual responsibility: protecting the individual child while safeguarding population health.[14]

Cross-cutting Challenges and Cost-effectiveness

Despite major advances in vaccine and monoclonal antibody science, clinicians continue to face significant implementation barriers that impede translation of these innovations into public-health impact. From a physician's standpoint, these challenges are multifactorial—economic, logistical, sociocultural, and ethical—and directly affect the ability to protect vulnerable pediatric populations. A primary concern is cost-effectiveness. While childhood vaccines remain among the most cost-efficient health interventions known, novel monoclonal antibody (mAb) therapies such as nirsevimab and next-generation biologics carry high production costs. In high-income countries, a single dose may exceed $400, placing it beyond reach for universal inclusion in national immunization programs. However, real-world modeling demonstrates that when targeted toward infants at highest risk—preterm, chronically ill, or immunodeficient—the incremental cost per quality-adjusted life year (QALY) compares favorably with existing pediatric interventions such as neonatal intensive care. Physicians engaged in policymaking must advocate for such risk-based prioritization. Logistical barriers further complicate rollout. Vaccines and biologics require stringent cold-chain maintenance and healthcare personnel trained in reconstitution and administration. In many low- and middle-income countries, pediatricians and community physicians face shortages of storage infrastructure, supply chain interruptions, and limited diagnostic surveillance, factors that collectively diminish the impact of even the most efficacious products.[15] Vaccine hesitancy represents another clinician-facing challenge. Misinformation, fear of adverse events, and distrust in pharmaceutical motives reduce uptake even in urban populations. Doctors remain the most trusted sources of medical advice, making physician-led communication campaigns essential. Empathetic counseling emphasizing safety monitoring, peer-reviewed evidence, and community benefit can substantially improve compliance. Equity also defines the ethical dimension of cost-effectiveness. Pediatricians practicing in resource-limited settings often confront moral dilemmas—allocating limited prophylaxis doses among many at-risk infants. Such decisions demand transparent prioritization frameworks grounded in disease burden data and fairness principles.[16] From a systems perspective, cost-effectiveness is dynamic, it evolves with economies of scale, patent expirations, and technological efficiencies. Clinicians participating in real-world evidence studies contribute invaluable data to refine these models. The eventual goal is not simply price reduction but value optimization maximizing health impact per resource invested. In essence, for physicians, the cost-effectiveness conversation is inseparable from clinical responsibility. Understanding not just how interventions work, but where, when, and for whom they yield the greatest benefit, transforms doctors from consumers of medical innovation into architects of equitable public-health policy.[17]

FUTURE DIRECTIONS AND CONCLUSION

The future of pediatric infectious disease prevention is entering a precision era — one where immunological insight, biotechnology, and clinical judgment converge. For physicians, the focus is shifting from isolated vaccine administration to integrated immunization strategies that combine maternal vaccination, neonatal monoclonal antibody prophylaxis, and early-childhood boosters to provide uninterrupted protection through the most vulnerable years of life. Precision vaccinology is emerging as a transformative concept. Advances in systems immunology and genetic profiling are enabling clinicians to predict vaccine responsiveness and adverse-event susceptibility at the individual level. In practice, this means that in the coming decade, pediatric vaccination schedules may become adaptive — tailored to each child's immune maturity, genetic background, and comorbidity profile. Such personalization will rely heavily on clinician-led data collection and feedback into immunization registries. The field of monoclonal antibody therapeutics is likewise evolving toward next-generation platforms: bispecific antibodies capable of binding multiple epitopes, nanobodies with enhanced tissue penetration, and antibody–drug conjugates designed for dual antiviral and immunomodulatory action. From a public-health perspective, integrating these technologies into national immunization programs will demand close collaboration between clinicians, epidemiologists, and policymakers. Pediatricians must continue to act as both advocates and implementers—ensuring that data-driven recommendations are translated into equitable access. Surveillance of breakthrough infections, long-term safety outcomes, and post-marketing pharmacovigilance should remain part of routine pediatric care. The future clinical landscape also emphasizes the need for education and communication. As misinformation threatens vaccine confidence, doctors must reinforce trust through transparent dialogue grounded in evidence and empathy. The physician's authority, when exercised ethically, remains the most powerful tool in sustaining public-health adherence.

CONCLUSION

Pediatric infectious disease prevention is undergoing a paradigm shift—from traditional immunization schedules toward integrated, evidence-based strategies that merge vaccines and monoclonal antibodies (mAbs) as complementary pillars of child health. For clinicians, this evolution signifies not only new preventive tools but also an expanded professional responsibility to interpret, implement, and advocate for these innovations within diverse healthcare contexts. From a clinical standpoint, long-acting mAbs such as nirsevimab have demonstrated that single-dose protection across an entire RSV season is achievable, while maternal immunization further bridges the early postnatal vulnerability period. The same principle extends to COVID-19, dengue, and influenza, where targeted vaccination supported by immunological surveillance has transformed pediatric care from reactive disease management to proactive immune defense. Physicians now operate within an ecosystem where understanding antibody kinetics, correlates of protection, and population-level herd immunity is as vital as mastering bedside diagnosis. The future of pediatric prophylaxis lies in precision vaccinology—adapting immunization strategies to the individual child's immune maturity, genetic background, and comorbidity profile. Such personalization demands close clinician involvement in data interpretation, adverse-event monitoring, and community education. Equally important are the ethical and economic dimensions: equitable access, transparent prioritization, and cost-effectiveness analyses ensure that innovation benefits not only those who can afford it but every child in need. As guardians of child health, physicians must champion cross-disciplinary collaboration—linking laboratory discoveries, public-health systems, and family trust. Their role extends beyond prescribing to policy advocacy, surveillance, and education, ensuring that each intervention achieves both clinical efficacy and societal impact. Ultimately, vaccines and monoclonal antibodies together redefine modern pediatrics. They offer an integrated continuum of protection—vaccines generating enduring adaptive immunity and mAbs providing rapid, immediate defense. The challenge ahead is not scientific discovery alone but the physician's capacity to translate innovation into equitable, sustainable care. By embracing this responsibility, clinicians will not only prevent infections but also shape a healthier, more resilient generation of children worldwide.

REFERENCES

1. Bahadir Z, Narayan P, Wolters R, Permar SR, Fouda G, Hessell AJ, Haigwood NL. Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment. Pediatrics. 2025 May 1;155(5):e2024068690.
2. Daggumati S, Carlson JC. Monoclonal Antibody Therapies for Children. 2025
3. Atanasov PY, Moneva-Sakelarieva MG, Kobakova YA, Ivanova SA, Becheva MV, Kirkova-Bogdanova AG, Chaneva MS, Atanasova VP, Todorov RF, Bashev NZ, Bashov IE. Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease–history, present, and future. Literature review. Pharmacia. 2025 Jun 25;72:1-8.
4. Lyke KE, Berry AA, Laurens MB, Winkler J, Joshi S, Koudjra AR, Butler L, Billingsley PF, Pascini T, Patil A, Sim BK. Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial. The Lancet Infectious Diseases. 2025 Sep 23.
5. Ávila-Agüero ML, Debbag R, Brenes-Chacón H, Brea-Del Castillo J, Falleiros-Arlant LH, Soriano-Fallas A, Torres Martínez CN, Dueñas L, Mascareñas-de Los Santos AH, Lopez P, Pujadas M. Advancing respiratory syncytial virus (RSV) prevention in Latin

America: updated recommendations from the Pediatric Infectious Diseases society of Latin America (SLIPE) expert group on RSV prevention. Expert Review of Vaccines. 2025 Dec 31.
6. Polistena B, Midulla F, Sotgiu G, d'Angela D, Di Virgilio R, Spandonaro F. Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment. Infectious Diseases and Therapy. 2025 Aug;14(8):1883-97.
7. Stobbelaar K, Jacobs L, Serrano-Cano FI, Fransen A, Van der Gucht W, Smet A, De Winter BY, Cos P, De Vos W, Van Hoorenbeeck K, Verhulst S. Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolates. mSphere. 2025 May 27;10(5):e00860-24.
8. Brigadoi G, Demarin GC, Boracchini R, Pierantoni L, Rossin S, Barbieri E, Tirelli F, Cantarutti A, Tempo G, Giaquinto C, Lanari M. Comparison between the viral illness caused by SARS-CoV-2, influenza virus, respiratory syncytial virus and other respiratory viruses in pediatrics. Viruses. 2024 Jan 27;16(2):199.
9. Kwon JH, Paek SH, Park SH, Kim MJ, Byun YH, Song HY. COVID-19, influenza, and RSV in children and adults: A clinical comparative study of 12,000 cases. Journal of Clinical Medicine. 2024 Mar 15;13(6):1702.
10. Feikin DR, Karron RA, Saha SK, Sparrow E, Srikantiah P, Weinberger DM, Zar HJ. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. The Lancet Infectious Diseases. 2024 May 1;24(5):e318-27.
11. Pandolfi E, Loconsole D, Chironna M, van Summeren J, Paget J, Raponi M, Russo L, Campagna I, Croci I, Concato C, Perno CF. Pre-COVID-19-pandemic RSV epidemiology and clinical burden in pediatric primary care in Italy: a comparative analysis across two regions for the 2019/2020 season. BMC Infectious Diseases. 2024 Apr 11;24(1):388.
12. Choi SH, Kim DH, Ahn JG, Yun KW, Eun BW, Lee J, Lee J, Lee TJ, Lee H, Jo DS, Cho EY. Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children. Clinical and Experimental Pediatrics. 2025 Sep 3;68(10):742.
13. Che Y. Cost-Effectiveness of New Monoclonal Antibody and Maternal Immunization for the Prevention of Respiratory Syncytial Virus (RSV) Disease in Infants: A Systematic Review.
14. Manzoni P, Baraldi E, Midulla F, Claris O, Dessardo S, Heikkinen T, Thwaites R, Paes B, Carbonell-Estrany X, Dobryanskyy D, Cetinkaya M. Systematic review and expert consensus on the use of long-acting monoclonal antibodies for prevention of respiratory syncytial virus disease: ARMADA (A dvancing R SV M anagement A nd D isease A wareness) Taskforce. InOpen Forum Infectious Diseases 2025 Jul 2 (p. ofaf396). Oxford University Press.
15. Getaneh AM, Li X, Mao Z, Johannesen CK, Barbieri E, Van Summeren J, Wang X, Tong S, Baraldi E, Phijffer E, Rizzo C. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine. 2023 Feb 24;41(9):1623-31.
16. Esposito S, Amirthalingam G, Bassetti M, Blasi F, De Rosa FG, Halasa NB, Hung I, Osterhaus A, Tan T, Torres JP, Vena A. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Frontiers in immunology. 2023 May 15;14:1162342.
17. Koltai M, Moyes J, Nyawanda B, Nyiro J, Munywoki PK, Tempia S, Li X, Antillon M, Bilcke J, Flasche S, Beutels P. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa. BMC medicine. 2023 Mar 31;21(1):120.